Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Janssen and Grünenthal sue Watson over Nucynta generic
Americas
Johnson & Johnson’s pharmaceutical subsidiary Janssen and Germany-based pharmaceutical company Grünenthal have sued Watson Laboratories for infringing patents related to painkiller Nucynta (tapentadol hydrochloride).   24 July 2014
Court denies Lilly’s application to block GSK SPC
Big Pharma
The English High Court has dismissed an application by Eli Lilly to stop Human Genome Sciences from getting an SPC based on a marketing authorisation Lilly may receive for a new drug.   23 July 2014
Mylan lands injunction against GSK’s Paroxetine
Americas
The US District Court for the District of New Jersey has granted Mylan its motion for a permanent injunction against GlaxoSmithKline’s (GSK’s) Paroxetine CR.   22 July 2014
Americas
Steptoe & Johnson LLP has added to its IP team with the appointment of patent litigator John Molenda.   22 July 2014
Biotechnology
The Attorney General for the Court of Justice of the European Union has issued an opinion on the meaning of the term ‘human embryos’ that could "significantly restrict" the scope of the Brüstle decision of 2011.   21 July 2014
Europe
The Medicines Patent Pool (MPP) has announced seven new sub-licensing agreements to make generic HIV medicines atazanavir (ATV) and dolutegravir (DTG).   18 July 2014
Americas
Novartis’s eye care unit Alcon Pharmaceuticals has sued Hyderabad-based Aurobindo Pharma for infringing two patents covering its eye drop solution Vigamox (moxifloxacin hydrochloride) at the US District Court for the District of Delaware.   17 July 2014
Big Pharma
The England and Wales High Court has refused Pfizer subsidiary Pharmacia’s request to stay Actavis’s patent revocation action against it.   17 July 2014
Asia
The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).   16 July 2014
Americas
The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.   15 July 2014